Healx names Anthony Hall as CMO

4 February 2020

The UK’s Healx, an AI-powered and patient-inspired technology company, today announced the appointment of Dr Anthony Hall as chief medical officer (CMO).

Dr Hall will be responsible for progressing the company’s rare disease drug candidates through the clinic, with an initial focus on initiating the company’s clinical trial for the treatment of Fragile X syndrome. The trial is due to commence in 2020 and will be conducted in association with the FRAXA Research Foundation.

Prior to joining Healx, Dr Hall worked as CMO at Aparito and as therapeutic area head of orphan drugs at Mereo BioPharma (AIM: MPH). He previously co-founded and successfully sold PSR, a Dutch CRO specializing in drug development for rare diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK